Search results for "PTEN Phosphohydrolase"

showing 10 items of 41 documents

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance

2012

// James A. McCubrey 1 , Linda S. Steelman 1 , William H. Chappell 1 , Stephen L. Abrams 1 , Richard A. Franklin 1 , Giuseppe Montalto 2 , Melchiorre Cervello 3 , Massimo Libra 4 , Saverio Candido 4 , Grazia Malaponte 4 , Maria C. Mazzarino 4 , Paolo Fagone 4 , Ferdinando Nicoletti 4 , Jorg Basecke 5 , Sanja Mijatovic 6 , Danijela Maksimovic-Ivanic 6 , Michele Milella 7 , Agostino Tafuri 8 , Francesca Chiarini 9 , Camilla Evangelisti 9 , Lucio Cocco 10 , Alberto M. Martelli 9,10 1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA 2 Department of Internal Medicine and Specialties, University of Palermo, Palermo, Italy 3 Consi…

MAPK/ERK pathwaymedicine.medical_treatmentPI3KTargeted therapyTargeted therapyPhosphatidylinositol 3-Kinases0302 clinical medicineNeoplasmsTreatment resistanceExtracellular Signal-Regulated MAP KinasesPhosphoinositide-3 Kinase InhibitorsGenetics0303 health sciencesbiologyCancer stem cellsTOR Serine-Threonine KinasesMAP Kinase Kinase KinasesDiscovery and development of mTOR inhibitorshumanities3. Good healthOncology030220 oncology & carcinogenesismTORSignal TransductionProto-Oncogene Proteins B-rafReviewsAntineoplastic Agents03 medical and health sciencesCell Line TumormedicineHumansPTENProtein kinase BPI3K/AKT/mTOR pathway030304 developmental biologybusiness.industryAkt; Cancer stem cells; mTOR; PI3K; Raf; Targeted therapy; Therapy resistanceAktPTEN PhosphohydrolaseTherapy resistanceRafProtein phosphatase 2Targeted Therapy Therapy Resistance Cancer Stem Cells Raf Akt PI3K mTORDrug Resistance NeoplasmMutationras ProteinsCancer researchbiology.proteinbusinessProto-Oncogene Proteins c-akt
researchProduct

Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine

2009

Background: Despite having a dramatically larger surface area than the large intestine, the small intestine is an infrequent site for the development of adenocarcinoma. To better understand the molecular abnormalities in small bowel adenocarcinoma (SBA), we characterised a number of candidate oncogenic pathways and the immunophenotype of this rare cancer. Methods: Tissue microarrays were constructed from tumour samples from 54 patients with all stages of the disease. Immunohistochemistry and microsatellite instability (MSI) testing were conducted. Results: The profile of cytokeratin 20 and 7 coexpression was variable, but expression of caudal type homeobox transcription factor 2 (CDX2) was …

MaleCancer ResearchPathologyReceptor ErbB-2Kaplan-Meier EstimateDNA Mismatch Repairchemistry.chemical_compoundDuodenal NeoplasmsCDX2 Transcription Factorsmall bowel adenocarcinomaCDX2Letter to the EditorOligonucleotide Array Sequence Analysisvascular endothelial growth factorbiologyMiddle AgedNeoplasm ProteinsErbB ReceptorsVascular endothelial growth factormismatch repairOncologyimmunohistochemistryKeratinsAdenocarcinomaFemaleMicrosatellite InstabilityAdultmedicine.medical_specialtyAdenocarcinomaImmunophenotypingCytokeratinGrowth factor receptormedicineHumansPTENAgedHomeodomain ProteinsJejunal NeoplasmsGene Expression ProfilingPTEN PhosphohydrolaseMicrosatellite instabilityCancerGenes erbB-1OncogenesGenes erbB-2medicine.diseasedigestive system diseasesIleal NeoplasmsReceptors Vascular Endothelial Growth Factorchemistrybiology.proteinTranslational Therapeuticsepidermal growth factor receptorBritish Journal of Cancer
researchProduct

miR-20b and miR-451a Are Involved in Gastric Carcinogenesis through the PI3K/AKT/mTOR Signaling Pathway: Data from Gastric Cancer Patients, Cell Line…

2020

Gastric cancer (GC) is one of the most common and lethal gastrointestinal malignancies worldwide. Many studies have shown that development of GC and other malignancies is mainly driven by alterations of cellular signaling pathways. MicroRNAs (miRNAs) are small noncoding molecules that function as tumor-suppressors or oncogenes, playing an essential role in a variety of fundamental biological processes. In order to understand the functional relevance of miRNA dysregulation, studies analyzing their target genes are of major importance. Here, we chose to analyze two miRNAs, miR-20b and miR-451a, shown to be deregulated in many different malignancies, including GC. Deregulated expression of miR…

MaleCell signalingAntagonists & inhibitorsCaveolin 1ApoptosisCatalysisTuberous Sclerosis Complex 1 ProteinArticleInorganic Chemistrylcsh:ChemistryMicePhosphatidylinositol 3-KinasesStomach NeoplasmsCell Line TumormicroRNAPTENAnimalsHumans616.33-006.6 [udc]Physical and Theoretical ChemistryMolecular BiologyProtein kinase Blcsh:QH301-705.5SpectroscopyPI3K/AKT/mTOR pathwaybiologyTOR Serine-Threonine Kinasesgastric cancerOrganic ChemistryPTEN PhosphohydrolaseAntagomirsGeneral MedicineStomach neoplasms ; genetics ; MicroRNAs ; genetics ; Phosphoinositide-3 Kinase Inhibitors ; Phosphatidylinositol 3-Kinase ; metabolism ; Proto-Oncogene Proteins c-akt ; antagonists&inhibitors ; Proto-Oncogene Proteins c-akt ; metabolism ; TOR Serine-Threonine Kinases ; antagonists&inhibitors ; TOR Serine-Threonine Kinases ; metabolism ; Signal transduction ; drug effects ; Disease models animal ; MicemiR-451aComputer Science ApplicationsmicroRNAsDisease Models Animallcsh:Biology (General)lcsh:QD1-999biology.proteinCancer researchFemalemiR-20bSignal transductionCarrier ProteinsProto-Oncogene Proteins c-aktTXNIPSignal TransductionPI3K/AKT/mTOR signaling pathwayInternational Journal of Molecular Sciences
researchProduct

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mtor pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

2011

Dysregulated signaling through the Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways is often the result of genetic alterations in critical components in these pathways or upstream activators. Unrestricted cellular proliferation and decreased sensitivity to apoptotic-inducing agents are typically associated with activation of these pro-survival pathways. This review discusses the functions these pathways have in normal and neoplastic tissue growth and how they contribute to resistance to apoptotic stimuli. Crosstalk and commonly identified mutations that occur within these pathways that contribute to abnormal activation and cancer growth will also be addressed. Finally the recently described …

MaleMAPK/ERK pathwayAgingMAP Kinase Signaling SystemCancer aging RAF MEK mTORApoptosisReviewBiologyPI3KModels BiologicalApoptosis; Cancer; Kinases; MEK; MTOR; PI3K; Protein phosphorylation; RAF; Signal transductionMicePhosphatidylinositol 3-Kinases03 medical and health sciences0302 clinical medicineCancer stem cellNeoplasmscancerAnimalsHumansPTENProtein kinase BCellular SenescencePI3K/AKT/mTOR pathwayCell Proliferation030304 developmental biology0303 health sciencesKinaseTOR Serine-Threonine KinasesapoptosisPTEN PhosphohydrolaseRafCell BiologyMEKprotein phosphorylation3. Good healthCell biologyCrosstalk (biology)kinases030220 oncology & carcinogenesisMutationmTORCancer researchbiology.proteinFemaleraf KinasesProto-Oncogene Proteins c-aktCell agingsignal transduction
researchProduct

Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice.

2010

BACKGROUND & AIMS: The limited clinical response observed in many patients with colorectal cancer may be related to the presence of chemoresistant colorectal can- cer stem cells (CRC-SCs). Bone morphogenetic protein 4 (BMP4) promotes the differentiation of normal colonic stem cells. We investigated whether BMP4 might be used to induce differentiation of CRC-SCs and for therapeutic purposes. METHODS: CRC-SCs were isolated from 25 tumor samples based on expression of CD133 or using a selection culture medium. BMP4 expression and activity on CRC-SCs were evaluated in vitro; progeny of the stem cells were evaluated by immunofluorescence, immuno- blot, and flow cytometry analyses. The potential …

MaleOrganoplatinum CompoundsCellular differentiationDrug ResistanceApoptosisBone Morphogenetic Protein 4Colon Cancer; Drug Resistance; Neoplasia; Tumor Resistance to Chemotherapy; AC133 Antigen; Adenomatous Polyposis Coli; Aged; Aged 80 and over; Animals; Antigens CD; Antineoplastic Agents; Apoptosis; Bone Morphogenetic Protein 4; Cell Differentiation; Cells Cultured; Colorectal Neoplasms; Female; Fluorouracil; Glycoproteins; Humans; Male; Mice; Microsatellite Instability; Middle Aged; Mutation; Neoplastic Stem Cells; Organoplatinum Compounds; PTEN Phosphohydrolase; Peptides; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Smad4 Protein; GastroenterologyMice80 and overBone morphogenetic protein receptorAC133 AntigenCells CulturedSmad4 ProteinAged 80 and overCulturedColon Cancerintegumentary systemGastroenterologyCell DifferentiationBMP4 colon stem cellsMiddle AgedCDOxaliplatinTumor Resistance to ChemotherapyBone morphogenetic protein 4Adenomatous Polyposis Coliembryonic structuresNeoplastic Stem CellsFemaleMicrosatellite InstabilityFluorouracilStem cellColorectal Neoplasmsanimal structuresCellsAntineoplastic AgentsBiologyBone morphogenetic proteinSettore MED/04 - PATOLOGIA GENERALECancer stem cellAntigens CDPTENAnimalsHumansAntigensneoplasmsPI3K/AKT/mTOR pathwayAgedGlycoproteinsNeoplasiaHepatologyPTEN Phosphohydrolasedigestive system diseasesMutationCancer researchbiology.proteinPhosphatidylinositol 3-KinasePeptidesProto-Oncogene Proteins c-aktGastroenterology
researchProduct

Immunopositivity for histone macroH2A1 isoforms marks steatosisassociated hepatocellular carcinoma.

2012

BackgroundHepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Prevention and risk reduction are important and the identification of specific biomarkers for early diagnosis of HCC represents an active field of research. Increasing evidence indicates that fat accumulation in the liver, defined as hepatosteatosis, is an independent and strong risk factor for developing an HCC. MacroH2A1, a histone protein generally associated with the repressed regions of chromosomes, is involved in hepatic lipid metabolism and is present in two alternative spliced isoforms, macroH2A1.1 and macroH2A1.2. These isoforms have been shown to predict lung and colon cancer recurrence but to ou…

MalePathologyMouseBiological Markers/metabolismEpidemiologyTumor Microenvironment/geneticsColorectal cancerGene ExpressionHepatocytes/metabolism/pathologyNonalcoholic SteatohepatitisHistonesFatty Liver/chemically induced/complications/genetics/metabolismMice0302 clinical medicineGastrointestinal CancersTumor MicroenvironmentPathologyProtein IsoformsDiethylnitrosamineSettore MED/49 - Scienze Tecniche Dietetiche ApplicateMice KnockoutRegulation of gene expression0303 health sciencesMultidisciplinaryProtein Isoforms/genetics/metabolismbiologyLiver DiseasesPTEN Phosphohydrolase/deficiency/geneticshepatocellular carcinoma biomarker histone variant steatosis epigeneticsLiver NeoplasmsQFatty liverRHistone ModificationAnimal ModelsImmunohistochemistry3. Good healthHistoneOncology030220 oncology & carcinogenesisHepatocellular carcinomaMedicineEpigeneticsCarcinoma Hepatocellular/etiology/genetics/metabolism/pathologyResearch ArticleGene isoformmedicine.medical_specialtyCarcinoma HepatocellularHistologyClinical Research DesignScienceGastroenterology and HepatologyDiet High-Fat03 medical and health sciencesModel OrganismsDiagnostic MedicineGastrointestinal TumorsGeneticsCancer GeneticsCancer Detection and DiagnosisEarly DetectionmedicineAnimalsHumansAnimal Models of DiseaseObesityddc:612BiologyHistones/genetics/metabolismNutrition030304 developmental biologyCell NucleusCell Nucleus/genetics/metabolism/pathologyTumor microenvironmentbusiness.industryPTEN PhosphohydrolaseCancers and NeoplasmsHepatocellular Carcinomamedicine.diseasedigestive system diseasesFatty LiverBiomarker EpidemiologyGene Expression RegulationHepatocytesbiology.proteinLiver Neoplasms/etiology/genetics/metabolism/pathologySteatosisbusinessBiomarkersGeneral Pathology
researchProduct

PTEN Deletion in Adult Mice Induces Hypoinsulinemia With Concomitant Low Glucose Levels

2022

The PI3K/AKT pathway, negatively regulated by PTEN, plays a paramount role in glucose metabolism regulation due to its activation by the insulin receptor signaling pathway. We generated a PTEN-KO mouse to evaluate the systemic effect of the overactivation of the PI3K/AKT pathway in insulin signaling and glucose homeostasis. Our results demonstrate that PTEN-KO mice show very low glucose levels in the fasted state, which poorly respond to glucose and pyruvate administration. Insulinemia decreased without alterations in pancreatic islets. Among the possible reasons, we uncover the deregulation of the expression of proximal tubule glucose transporter and consequent glycosuria. Moreover, we evi…

Mice KnockoutBioquímicaMicePhosphatidylinositol 3-KinasesBiologiaGlucoseEndocrinology Diabetes and MetabolismGluconeogenesisPTEN PhosphohydrolaseAnimalsInsulinEndocrine System DiseasesProto-Oncogene Proteins c-akt
researchProduct

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

2010

An important molecular target for metastatic CRC treatment is the epidermal growth factor receptor (EGFR). Many potential biomarkers predictive of response to anti-EGFR monoclonal antibodies (cetuximab and panitumumab) have been retrospectively evaluated, including EGFR activation markers and EGFR ligands activation markers. With regard to the "negative predictive factors" responsible for primary or intrinsic resistance to anti-EGFR antibodies a lot of data are now available. Among these, KRAS mutations have emerged as a major predictor of resistance to panitumumab or cetuximab in the clinical setting and several studies of patients receiving first and subsequent lines of treatment have sho…

OncologyColorectal cancerSettore MED/06 - Oncologia MedicaCetuximabDrug resistancemedicine.disease_causeEpidermal growth factor receptorEGFR; KRAS; Driver mutations; Monoclonal antibodiesCetuximabbiologyPanitumumabAntibodies MonoclonalGeneral MedicinePrognosisAntibodies Anti-IdiotypicErbB ReceptorsGene Expression Regulation NeoplasticOncologyMonoclonalKRASColorectal Neoplasmsmedicine.drugProto-Oncogene Proteins B-rafmedicine.medical_specialtymedicine.drug_classEGFRMonoclonal antibodyAntibodies Monoclonal HumanizedProto-Oncogene Proteins p21(ras)Predictive Value of TestsInternal medicineProto-Oncogene ProteinsmedicineBiomarkers TumorKRASPanitumumabHumansRadiology Nuclear Medicine and imagingneoplasmsbusiness.industryPTEN PhosphohydrolaseMembrane ProteinsDriver mutationmedicine.diseasedigestive system diseasesDrug Resistance NeoplasmMutationCancer researchbiology.proteinras ProteinsMonoclonal antibodiesbusiness
researchProduct

Pharmacogenomics of cetuximab in metastatic colorectal carcinoma

2014

Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to important developments in the understanding of cetuximab biology. In light of knowledge gained from recent trials, the efficacy of cetuximab has been clearly demonstrated to depend upon RAS mutational status, moreover cetuximab should only be used in a subset of patients who may benefit. In this article, we critically review clinical and pharmacogenetic issues of cetuximab, focusing on the cost–effectiveness involved with the use of the drug.

OncologySettore MED/06 - Oncologia MedicaCost effectivenessColorectal cancercost-effectiveneCetuximabColorectal NeoplasmPharmacologyAntineoplastic AgentPhosphatidylinositol 3-KinasesMutational statusMedicineNeoplasm MetastasiscetxuximabProto-Oncogene ProteinTOR Serine-Threonine KinaseCetuximabPharmacogeneticTOR Serine-Threonine KinasesNeoplasm MetastasiErbB ReceptorsMolecular MedicineColorectal NeoplasmsHumanmedicine.drugProto-Oncogene Proteins B-rafmedicine.medical_specialtypharmacogenomicEGFRAntineoplastic AgentsAntibodies Monoclonal HumanizedresistanceProto-Oncogene Proteins p21(ras)Geneticcolorectal carcinomaProto-Oncogene ProteinsInternal medicineGeneticsHumanspredictivecost-effectivenessneoplasmspharmacogenomicsPharmacologybusiness.industryPTEN Phosphohydrolaseras Proteinmedicine.diseasedigestive system diseasesDrug Resistance NeoplasmPharmacogeneticsPharmacogenomicsMutationras ProteinsReceptor Epidermal Growth FactorPhosphatidylinositol 3-KinasebusinessProto-Oncogene Proteins c-aktPharmacogeneticsRASPharmacogenomics
researchProduct

Response to Stanich et al.: Correspondence regarding-PTEN hamartoma tumor syndromes in childhood-Description of two cases and a proposal for follow-u…

2014

The follow-up protocol, which we describe in this study can serve as a practical proposal for clinicians, and as a basis for future studies. We strongly urge the clinician to start an early surveillance of the gastrointestinal tract including regular endoscopy. The main management goals in PHTS patients are to detect colon cancer early, and to prevent polyp-related complications (bowel obstruction from intussusception). The presence of multiple nonmalignant polyps in patients with PTEN mutations may complicate noninvasive methods of colon evaluation [Tan et al., 2012]. In addition, there is a high variability in severity of polyps progression, and the malignant potential of these lesions is…

Oncologymedicine.medical_specialtybiologybusiness.industryMedicine (all)PTEN Phosphohydrolasemedicine.diseaseptenGeneticInternal medicineGeneticsmedicinebiology.proteinHamartomaPTENHumansFemalebusinessHamartoma Syndrome MultipleGenetics (clinical)Human
researchProduct